Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

Author's Avatar
May 31, 2022

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulation implantable neurostimulator (INS).